Hikma Pharmaceuticals Plc Potential Acquisition (8957M)
26 Gennaio 2021 - 9:01AM
UK Regulatory
TIDMHIK
RNS Number : 8957M
Hikma Pharmaceuticals Plc
26 January 2021
London, 26 January 2021 - The Board of Hikma Pharmaceuticals Plc
(Hikma) notes the disclosure made today to the Egyptian Exchange by
GlaxoSmithKline S.A.E. (GSK SAE), the listed Egyptian subsidiary
within the GlaxoSmithKline plc group of companies (GSK). Hikma
confirms that it has entered into a non-binding term sheet with GSK
for the purposes of potentially acquiring GSK's interests in
certain entities that conduct, and certain assets comprising, GSK's
pharmaceutical and consumer commercialisation and manufacturing
business in Egypt and GSK's pharmaceutical business in Tunisia (the
Proposed Transaction).
In addition and subject to receipt of GSK SAE's board consent,
Hikma hereby announces that it expects to conduct a due diligence
exercise, the results of which will form the basis for further
discussions with GSK in connection with the Proposed
Transaction.
The Proposed Transaction is subject to a number of conditions,
including the finalisation of definitive and legally binding
documents and the completion of due diligence by Hikma. As such,
there can be no guarantee at this stage that the Proposed
Transaction will progress.
Hikma will provide further updates in due course.
Enquiries:
Hikma:
Susan Ringdal
EVP, Strategic Planning and Global +44 (0)20 7399 2760 / +44 (0)7776
Affairs 477050
Guy Featherstone +44 (0)20 3892 4389 / +44 (0)7795
Senior Investor Relations Manager 896738
Layan Kalisse +44 (0)20 7399 2788 / +44 (0)7970
Investor Relations Analyst 709912
Teneo (Press):
Charles Armitstead/ Camilla Cunningham, +44 (0)7703 330 269/ +44 (0)7464 982 426
About Hikma
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC:
HKMPY) (LEI: 549300BNS685UXH4JI75) (rated BBB-/stable S&P,
BBB-/stable Fitch and Ba1/stable Moody's)
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,600 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information, please visit: www.hikma.com .
(c)2021 Hikma Pharmaceuticals PLC. All rights reserved.
- ENDS -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACQDKABKFBKKKDB
(END) Dow Jones Newswires
January 26, 2021 03:01 ET (08:01 GMT)
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Apr 2023 a Apr 2024
